Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDROXYZINE PAMOATE vs HYDROXYZINE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Hydroxyzine pamoate is a piperazine derivative with antihistamine (H1 receptor antagonist) and anticholinergic properties. It also has sedative, anxiolytic, and antiemetic effects, likely mediated through suppression of subcortical regions of the central nervous system.
Hydroxyzine is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors in the gastrointestinal tract, blood vessels, and respiratory tract. It also exhibits sedative, anxiolytic, and antiemetic properties, possibly through central nervous system depression and anticholinergic effects.
FDA approved: Pruritus due to allergic conditions such as chronic urticaria, atopic dermatitis, and contact dermatitis,FDA approved: Anxiety and tension (as a sedative),Off-label: Nausea and vomiting (antiemetic),Off-label: Preoperative sedation
Pruritus due to allergic conditions such as urticaria, atopic dermatitis, and contact dermatitis,Anxiety and tension (as a short-term management in adults),Preoperative sedation and to reduce anxiety prior to surgery,Nausea and vomiting (off-label),Insomnia (off-label)
Oral: 50-100 mg every 6 hours as needed for pruritus or anxiety; maximum 600 mg/day. IM: 25-100 mg every 4-6 hours as needed.
25-100 mg orally 3-4 times daily; 50-100 mg IM every 4-6 hours as needed. Maximum oral dose: 600 mg/day in divided doses.
Terminal elimination half-life is approximately 20 hours (range 14-25 hours) in adults; may be prolonged in elderly or hepatic impairment.
Terminal elimination half-life: 14-25 hours (mean ~20 h). In elderly or hepatic impairment, may be prolonged; antihistamine effect persists beyond half-life due to active metabolite.
Hydroxyzine is extensively metabolized in the liver primarily via CYP3A4 and CYP2D6 isoenzymes. The major metabolite is cetirizine, an active carboxylic acid metabolite.
GFR 10-50 m L/min: Administer every 12 hours. GFR <10 m L/min: Administer every 24 hours or avoid use due to risk of accumulation.
GFR 10-50 m L/min: administer every 12 hours. GFR <10 m L/min: administer every 24 hours. Not recommended for use in patients with severe renal impairment (e GFR <30 m L/min/1.73 m²) due to increased risk of neurotoxicity.
No FDA black box warning.
Hydroxyzine pamoate is classified as FDA Pregnancy Category C. Data in humans are limited; however, animal studies have shown teratogenic effects at high doses. There are no adequate and well-controlled studies in pregnant women. First trimester: Potential risk of fetal abnormalities cannot be ruled out; use only if clearly needed. Second and third trimesters: May cause neonatal respiratory depression, hypotonia, and withdrawal symptoms if used near term.
Hydroxyzine is generally considered low risk for teratogenicity. Animal studies have shown no consistent evidence of fetal harm. Human data are limited but do not indicate a significant increase in major malformations. In the first trimester, use only if clearly needed. In the second and third trimesters, there is a potential risk of neonatal respiratory depression, hypotonia, and withdrawal symptoms if used near term or in high doses. Avoid use during labor and delivery due to potential maternal hypotension and fetal effects.
Hydroxyzine pamoate is a first-generation antihistamine with sedative, anxiolytic, and antipruritic properties. It is often used for pre-operative sedation and management of anxiety. Note that it can cause significant QT prolongation, especially in patients with electrolyte abnormalities or concurrent use of other QT-prolonging drugs. Avoid use in patients with porphyria. Onset of sedation is rapid, making it useful for acute agitation. It is also effective for urticaria and other allergic pruritus. The pamoate salt is a long-acting formulation, with peak effects at 2-4 hours and a half-life of 20-25 hours. Always assess renal function in elderly patients to avoid excessive sedation and anticholinergic toxicity.
Hydroxyzine is a first-generation antihistamine with anxiolytic, sedative, and antiemetic properties. It is commonly used for pruritus, anxiety, and premedication. Avoid concurrent use with CNS depressants due to additive sedation. In elderly patients, risk of confusion and falls is increased; consider alternative therapies. Hydroxyzine has anticholinergic effects; use cautiously in patients with glaucoma, urinary retention, or prostatic hyperplasia. Note that hydroxyzine can cause QT prolongation at high doses or in combination with other QT-prolonging drugs.
No interactions on record
"The risk or severity of adverse effects can be increased when Hydroxyzine is combined with Nefazodone."
"Hydroxyzine may increase the QTc-prolonging activities of Mifepristone."
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Hydroxyzine."
HYDROXYZINE PAMOATE and HYDROXYZINE are distinct pharmacological agents. HYDROXYZINE PAMOATE belongs to the Antihistamine class and is primarily used for FDA approved: Pruritus due to allergic conditions such as chronic urticaria, atopic dermatitis, and contact dermatitisFDA approved: Anxiety and tension (as a sedative)Off-label: Nausea and vomiting (antiemetic)Off-label: Preoperative sedation. HYDROXYZINE belongs to the Antihistamine class and is primarily used for Pruritus due to allergic conditions such as urticaria, atopic dermatitis, and contact dermatitisAnxiety and tension (as a short-term management in adults)Preoperative sedation and to reduce anxiety prior to surgeryNausea and vomiting (off-label)Insomnia (off-label). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. HYDROXYZINE PAMOATE carries a safety status of Category A/B, whereas HYDROXYZINE safety is classified as Category A/B. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Hydroxyzine is primarily metabolized by the liver via CYP3A4 and CYP2D6 isoenzymes. The major active metabolite is cetirizine, which is also a histamine H1 receptor antagonist.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal elimination accounts for approximately 50% of metabolites.
Renal: approximately 70% as metabolites, less than 1% unchanged. Fecal/biliary: minor. Cetirizine (active metabolite) also renally eliminated.
Approximately 93% bound to plasma proteins, primarily albumin.
93% bound to plasma proteins, primarily albumin.
Approximately 16 L/kg (range 13-20 L/kg); indicates extensive tissue distribution.
16 L/kg (range 7-20 L/kg), indicating extensive tissue distribution; higher Vd suggests large extravascular binding.
Oral: approximately 100% (well absorbed); IM: approximately 100%.
Oral: approximately 80%; IM: >80% (almost complete and rapid); IV: 100%.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Use with caution; maximum 50 mg/day or avoid use.
Child-Pugh Class B: reduce dose by 50% and/or increase dosing interval to every 12-24 hours. Child-Pugh Class C: use with caution; consider alternative agent or reduce dose by 75% and administer every 24 hours.
Oral: For pruritus: 0.5-1 mg/kg/dose every 6-8 hours. For anxiety: <6 years: 50 mg/day divided; ≥6 years: 50-100 mg/day divided. IM: 0.5-1 mg/kg/dose every 4-6 hours.
Oral: 2 mg/kg/day in divided doses every 6-8 hours. Maximum: 50 mg/day for children <6 years; 100 mg/day for 6-12 years. IM: 0.5-1 mg/kg every 6-8 hours, not to exceed 50 mg per dose.
Start at lower end of dosing range (25 mg orally) due to increased sensitivity and anticholinergic effects; caution with sedation and hypotension.
Initiate at lowest dose (25 mg orally 3-4 times daily) and titrate cautiously due to increased risk of sedation, confusion, and anticholinergic effects. Maximum recommended dose: 100 mg/day in divided doses.
There is no FDA black box warning for hydroxyzine.
No significant food interactions. However, taking with food may reduce GI upset. Avoid alcohol and grapefruit juice, which can alter drug metabolism (minimal effect, but caution).
Hydroxyzine may be taken with or without food. Grapefruit juice may increase hydroxyzine serum concentrations and risk of adverse effects; avoid concurrent consumption. High-fat meals can delay but not significantly reduce absorption. No other food restrictions are required.
Hydroxyzine is excreted in human breast milk; the milk-to-plasma ratio is not well established. The American Academy of Pediatrics considers hydroxyzine compatible with breastfeeding, but caution is advised due to potential for infant sedation and irritability. Monitor infant for drowsiness and feeding difficulties.
Hydroxyzine is excreted into breast milk in small amounts. The milk-to-plasma ratio is estimated at approximately 0.5. In infants, it may cause sedation, irritability, or poor feeding. Because of the potential for serious adverse reactions in nursing infants, consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for hydroxyzine and any potential adverse effects on the breastfed infant. Alternatives with better safety profiles may be preferred.
Pregnancy may alter hydroxyzine pharmacokinetics due to increased volume of distribution and clearance. However, specific dose adjustment guidelines are lacking. Use the lowest effective dose for the shortest duration. Consider reduced dosing in third trimester due to potential accumulation in the fetus and neonate.
Pharmacokinetic changes in pregnancy (increased volume of distribution, reduced plasma albumin, and altered hepatic metabolism) may affect hydroxyzine concentrations. However, specific dose adjustments for pregnancy are not well-established. Clinical monitoring for efficacy and adverse effects is recommended, and using the lowest effective dose for the shortest duration is prudent. No routine dose adjustment is mandated, but individual patient response should guide therapy.
Take exactly as prescribed; do not increase dose or frequency without consulting your healthcare provider.,This medication may cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they can increase sedation.,Report any irregular heartbeat, fainting, or seizures immediately.,Do not take with other antihistamines or medications containing antihistamines (e.g., cold and allergy products).,If you are pregnant, planning to become pregnant, or breastfeeding, discuss with your doctor before use.,Store at room temperature, away from moisture and heat.,Do not crush or chew extended-release capsules; swallow whole.
Take hydroxyzine exactly as prescribed and do not exceed the recommended dose.,Avoid driving or operating heavy machinery until you know how hydroxyzine affects you, as it may cause drowsiness or dizziness.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, opioids) while taking hydroxyzine.,Notify your doctor if you experience blurred vision, dry mouth, difficulty urinating, or rapid heartbeat.,Do not stop taking hydroxyzine abruptly if using for anxiety; consult your doctor for a taper plan.,Store at room temperature, away from moisture and heat.